lanthionine has been researched along with angiotensin ii, des-phe(8)- in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Franklin, R; Kuipers, A; Moll, GN; Wagner, E | 1 |
| Abbate, M; Benigni, A; Cassis, P; Cerullo, D; Corna, D; Locatelli, M; Remuzzi, G; Rottoli, D; Villa, S; Zoja, C | 1 |
| Mescheder, A; Moll, GN; Namsolleck, P; Richardson, A | 1 |
3 other study(ies) available for lanthionine and angiotensin ii, des-phe(8)-
| Article | Year |
|---|---|
Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.
Topics: Alanine; Angiotensin I; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Insulin; Mice; Mice, Inbred C57BL; Peptide Fragments; Streptozocin; Sulfides; Treatment Outcome | 2019 |
Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
Topics: Alanine; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Half-Life; Humans; Kidney Glomerulus; Lisinopril; Male; Mice; Mice, Transgenic; Microscopy, Electron, Transmission; Peptide Fragments; Peptides, Cyclic; Proteinuria; Sulfides | 2019 |
LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study.
Topics: Alanine; Angiotensin I; Animals; Arthropod Proteins; Dogs; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Oligopeptides; Peptide Fragments; Peptides; Proteolysis; Rats; Receptors, G-Protein-Coupled; Sulfides | 2021 |